Lagroben

Carmellose Sodium, the active ingredient in Lagroben, is a ophthalmic lubricant presented as an ophthalmic solution for topical ocular use. It treats dry eye syndrome and ocular surface irritation in adults. GNH USA supplies Lagroben as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lagroben (carmellose sodium) is used to manage dry eye and related ocular surface conditions.

- Dry eye syndrome: provides lubrication and stabilises the tear film to relieve discomfort. - Ocular surface irritation: reduces friction and protects the cornea from environmental stress. - Lubrication during ocular surgery: maintains moisture and protects ocular tissues intraoperatively.

Lagroben is generally well tolerated, but ocular preparations can cause local reactions.

Common Side Effects: - Transient burning or stinging sensation after instillation. - Temporary blurred vision. - Mild ocular redness. - Foreign‑body feeling in the eye. - Mild allergic conjunctivitis. - Slight eyelid swelling.

Serious or Rare Side Effects: - Severe allergic reaction, including anaphylaxis. - Corneal ulcer or epithelial defect. - Persistent eye pain. - Sudden loss of vision. - Severe intra‑ocular inflammation. - Secondary eye infection.

Before using Lagroben, consider the following safety measures.

- Allergy assessment: verify no known hypersensitivity to carmellose sodium or related compounds. - Contact lens wearers: remove lenses before instillation and wait before reinserting. - Concurrent eye medications: administer Lagroben at least 5 minutes apart to avoid dilution. - Pregnancy and lactation: use only if clearly needed, as safety data are limited. - Active eye infection: evaluate before use, as the product may mask symptoms. - Store at room temperature: keep in the original container, protect from light and moisture.

Lagroben may interact with other ophthalmic agents; monitor patients accordingly.

Major Interactions (Avoid): - Concurrent use with ophthalmic anesthetics: may increase corneal toxicity. - Use with preservative‑containing drops: risk of additive irritation. - Systemic antihistamines: may reduce tear production, diminishing therapeutic effect.

Moderate Interactions (Monitor Closely): - Contact lens solutions: may affect the viscosity of the drop. - Topical steroids: monitor for delayed corneal healing. - Anti‑glaucoma eye drops: observe intra‑ocular pressure for any unexpected changes.